NCI ID NCI-2021-03567
NCT ID NCT04928599
Anatomic Sites Lymphoid Leukemia
Minimum Age 18 Years
Maximum Age 999 Years
Gender BOTH
Lead Org Children's Oncology Group
Principal Investigator Melissa Parsons Beauchemin
NCI Site View on

Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States

The overall goals of this study are to measure parents’ financial distress (worry or anxiety about money) during their child’s/adolescent’s treatment for acute lymphoblastic leukemia and whether it changes over time, and to learn what factors are associated with changes in financial distress. Information gathered from this study will inform future intervention studies that may mitigate financial distress for parents of children/adolescents being treated for acute lymphoblastic leukemia.


Inclusion Criterea

  • All Children’s Oncology Group (COG) NCI Community Oncology Research Program (National Cancer Institute [N]CORP) institutions are eligible for participation in this study upon first parent enrollment
  • Parents age 18 years and above are eligible for this study. Index child must be between the ages of 1 and 14.9 years at the time of the parent’s enrollment
  • Parents of an index child with newly diagnosed with de novo ALL are eligible for this study
  • Parent must speak English or Spanish in order to participate in the consent process and provide consent. The parent’s language skills must be sufficient to understand the study requirements and complete the survey and interview questions
  • At the parent’s entry to the study, the index child must be receiving induction chemotherapy for newly diagnosed ALL at the enrolling institution. The index child may be enrolled in therapeutic clinical ALL trials or receiving ALL therapy per standard of care
  • REGULARTORY REQUIREMENTS: All parents must sign a written informed consent for their participation in the study
  • REGULARTORY REQUIREMENTS: All institutional and NCI requirements for human studies must be met

Exclusion Criterea

  • Parents of index children with any of the following clinical characteristics will be excluded from the study: * KMT2A-R (formerly MLL-R) not receiving ALL therapy * Mixed-phenotype acute leukemia (MPAL) not receiving ALL therapy * Burkitt’s leukemia

Participating Clinics

Renown Regional Medical Center

1155 Mill Street
Reno, NV 89502